β-lactam Antibiotics &amp; Vancomycin Increase the Growth &amp; Virulence of
            <i>Candida</i>
            spp.

Cordeiro, Rossana de Aguiar; Evangelista, Antonio José de Jesus; Serpa, Rosana; Andrade, Ana Raquel Colares de; Mendes, Patrícia Bruna Leite; Franco, Jônatas da Silva; Oliveira, Jonathas Sales de; Alencar, Lucas Pereira de; Sales, Juscelino Chaves; Câmara, Lilia Maria Carneiro; Castelo-Branco, Débora de Souza Collares Maia; Brilhante, Raimunda Sâmia Nogueira; Sidrim, José Júlio Costa; Rocha, Marcos Fábio Gadelha

doi:10.2217/fmb-2018-0019

Cited by 13 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(Gowri et al 2016 ; O'Driscoll et al 2008 ; Mohamadzadeh et al 2020 ). However, studies have indicated that β-lactam antibiotics are unable to inhibit the growth of Candida species, and amoxicillin can increase the virulence of Candida krusei and Candida tropicalis in Caenorhabditis elegans (Aguiar Cordeiro et al 2018 ).…”

Section: Antibacterial Drugsmentioning

confidence: 99%

Drug repurposing strategies in the development of potential antifungal agents

Zhang

Liu

Zeng

et al. 2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

The morbidity and mortality caused by invasive fungal infections are increasing across the globe due to developments in transplant surgery, the use of immunosuppressive agents, and the emergence of drug-resistant fungal strains, which has led to a challenge in terms of treatment due to the limitations of three classes of drugs. Hence, it is imperative to establish effective strategies to identify and design new antifungal drugs. Drug repurposing is a potential way of expanding the application of existing drugs. Recently, various existing drugs have been shown to be useful in the prevention and treatment of invasive fungi. In this review, we summarize the currently used antifungal agents. In addition, the most up-to-date information on the effectiveness of existing drugs with antifungal activity is discussed. Moreover, the antifungal mechanisms of existing drugs are highlighted. These data will provide valuable knowledge to stimulate further investigation and clinical application in this field. Key points • Conventional antifungal agents have limitations due to the occurrence of drug-resistant strains. • Non-antifungal drugs act as antifungal agents in various ways toward different targets. • Non-antifungal drugs with antifungal activity are demonstrated as effective antifungal strategies.

show abstract

Section: Antibacterial Drugsmentioning

confidence: 99%

Drug repurposing strategies in the development of potential antifungal agents

Zhang

Liu

Zeng

et al. 2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…It has been previously shown that β-lactam antibiotics and vancomycin stimulate the planktonic growth and virulence of Candida spp. (Cordeiro et al, 2018). In the present study, we showed that β-lactams also stimulate C. albicans biofilms, by enhancing biomass production and metabolic activity and increasing the number of viable cells.…”

Section: Discussionmentioning

confidence: 99%

Cefepime and Amoxicillin Increase Metabolism and Enhance Caspofungin Tolerance of Candida albicans Biofilms

et al. 2019

Self Cite

View full text Add to dashboard Cite

It is well known that prolonged antibiotic therapy alters the mucosal microbiota composition, increasing the risk of invasive fungal infection (IFI) in immunocompromised patients. The present study investigated the direct effect of β-lactam antibiotics cefepime (CEF) and amoxicillin (AMOX) on biofilm production by Candida albicans ATCC 10231. Antibacterials at the peak plasmatic concentration of each drug were tested against biofilms grown on polystyrene surfaces. Biofilms were evaluated for biomass production, metabolic activity, carbohydrate and protein contents, proteolytic activity, ultrastructure, and tolerance to antifungals. CEF and AMOX enhanced biofilm production by C. albicans ATCC 10231, stimulating biomass production, metabolic activity, viable cell counts, and proteolytic activity, as well as increased biovolume and thickness of these structures. Nevertheless, AMOX induced more significant changes in C. albicans biofilms than CEF. In addition, it was shown that AMOX increased the amount of chitin in these biofilms, making them more tolerant to caspofungin. Finally, it was seen that, in response to AMOX, C. albicans biofilms produce Hsp70 – a protein with chaperone function related to stressful conditions. These results may have a direct impact on the pathophysiology of opportunistic IFIs in patients at risk.

show abstract

“…The in vivo efficacy of known antifungal drugs and a number of repurposed drugs have also been applied in the treatment of nematode candidiasis. Several azoles (Souza et al, 2018;Hernando-Ortiz et al, 2020), echinocandins (Souza et al, 2018), polyenes-particularly amphotericin B (Hernando-Ortiz et al, 2020), and b-lactam antibiotics (in combination with vancomycin) (De Aguiar Cordeiro et al, 2018) have been evaluated for their in vivo efficacy at varying effective concentrations in rescuing worms infected with Candida species (Table 6). Synthesized azole drugs, such as 1-(4cyclopropyl-1H-1,2,3-triazol-1-yl)-2-(2,4-difluorophenyl)-3-(1H-1,2,4-triazol-1-yl) propan-2-ol, have also been evaluated for both efficacy and cytotoxicity in a C. elegans model (Chen et al, 2017).…”

Section: Ahamefule Et Almentioning

confidence: 99%

Caenorhabditis elegans as an Infection Model for Pathogenic Mold and Dimorphic Fungi: Applications and Challenges

Ahamefule

Ezeuduji

Ogbonna

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The threat burden from pathogenic fungi is universal and increasing with alarming high mortality and morbidity rates from invasive fungal infections. Understanding the virulence factors of these fungi, screening effective antifungal agents and exploring appropriate treatment approaches in in vivo modeling organisms are vital research projects for controlling mycoses. Caenorhabditis elegans has been proven to be a valuable tool in studies of most clinically relevant dimorphic fungi, helping to identify a number of virulence factors and immune-regulators and screen effective antifungal agents without cytotoxic effects. However, little has been achieved and reported with regard to pathogenic filamentous fungi (molds) in the nematode model. In this review, we have summarized the enormous breakthrough of applying a C. elegans infection model for dimorphic fungi studies and the very few reports for filamentous fungi. We have also identified and discussed the challenges in C. elegans-mold modeling applications as well as the possible approaches to conquer these challenges from our practical knowledge in C. elegans-Aspergillus fumigatus model.

show abstract

β-lactam Antibiotics & Vancomycin Increase the Growth & Virulence of Candida spp.

Abstract: These results suggest that antimicrobial therapy may have a direct effect on the pathophysiology of invasive fungal infections in patients at risk.

Cited by 13 publications

References 15 publications

Drug repurposing strategies in the development of potential antifungal agents

Drug repurposing strategies in the development of potential antifungal agents

Cefepime and Amoxicillin Increase Metabolism and Enhance Caspofungin Tolerance of Candida albicans Biofilms

Caenorhabditis elegans as an Infection Model for Pathogenic Mold and Dimorphic Fungi: Applications and Challenges

Contact Info

Product

Resources

About